Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.
Publication/Presentation Date
5-1-2008
Abstract
BACKGROUND: Patients with American College of Cardiology/American Heart Association stage C/D heart failure experience substantial morbidity and mortality, but available interventions beyond standard medical and device therapies are limited. Nesiritide relieves dyspnea and reduces pulmonary congestion, but its risk profile is uncertain. Pilot data suggested a potential benefit of nesiritide given as serial outpatient infusions.
METHODS AND RESULTS: The Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial was a randomized, double-blind, placebo-controlled trial of outpatient serial nesiritide infusions for patients with American College of Cardiology/American Heart Association stage C/D heart failure. Patients with 2 recent heart failure hospitalizations, ejection fraction
CONCLUSIONS: Serial outpatient nesiritide infusions do not provide a demonstrable clinical benefit over intensive outpatient management of patients with advanced American College of Cardiology/American Heart Association stage C/D heart failure.
Volume
1
Issue
1
First Page
9
Last Page
16
ISSN
1941-3297
Published In/Presented At
Yancy, C. W., Krum, H., Massie, B. M., Silver, M. A., Stevenson, L. W., Cheng, M., Kim, S. S., Evans, R., & FUSION II Investigators (2008). Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circulation. Heart failure, 1(1), 9–16. https://doi.org/10.1161/CIRCHEARTFAILURE.108.767483
Disciplines
Medicine and Health Sciences
PubMedID
19808265
Department(s)
Department of Medicine
Document Type
Article